HIFα expression in VHL-deficient renal cancer cells is dependent on phospholipase D

Oncogene

Volumn 27, Issue 19, 2008, Pages 2746-2753

  Toschi, A ^a   Edelstein, J ^a   Rockwell, P ^a   Ohh, M ^b   Foster, D A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apoptosis; HIF ; Hypoxia; Phospholipase D; Survival signals; VHL

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PHOSPHOLIPASE D; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; PHOSPHOLIPASE D; PROTEIN BIOSYNTHESIS; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 42549109144     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210927     Document Type: Article

References (37)

1. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J et al. (2006). PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR. Nature 442: 779-785.
2. Chen Y, Rodrik V, Foster DA. (2005). Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene 24: 672-679.
3. Chen Y, Zheng Y, Foster DA. (2003). Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 22: 3937-3942.
4. Colley WC, Sung TC, Roll R, Jenco J, Hammond SM, Altshuller Y et al. (1997). Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr Biol 7: 191-201.
5. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. (2001). Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294: 1942-1945.
6. Foster DA. (2004). Targeting mTOR-mediated survival signals in anticancer therapeutic strategies. Exp Rev Anticancer Ther 4: 691-701.
7. Foster DA. (2006). Phospholipase D survival signals as a therapeutic target in cancer. Curr Sig Trans Ther 1: 295-303.
8. Foster DA. (2007). Regulation of mTOR by phosphatidic acid? Cancer Res 67: 1-4.
9. Foster DA, Xu L. (2003). Phospholipase D in cell proliferation and cancer. Mol Cancer Res 1: 789-800.
10. Gatenby RA, Gillies RJ. (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
11. Gordan JD, Simon MC. (2007). Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 17: 71-77.
12. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
13. Hickey MM, Simon MC. (2006). Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol 76: 217-257.
14. Hui L, Abbas T, Pielak R, Joseph T, Bargonetti J, Foster DA. (2004). Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Mol Cell Biol 24: 5677-5688.
15. Hui L, Rodrik V, Pielak RM, Zheng Y, Foster DA. (2005). mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J Biol Chem 280: 35829-35835.
16. Kaelin Jr WG. (2005). The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun 338: 627-638.
17. Kaelin Jr WG. (2007). The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13: 680s-684s.
18. Kondo K, Kim WY, Lechpammer M, Kaelin Jr WG. (2003). Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1: 439-444.
19. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin Jr WG. (2002). Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246.
20. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW et al. (1998). Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18: 732-741.
21. Maxwell PH. (2005). The HIF pathway in cancer. Semin Cell Dev Biol 16: 523-530.
22. Maynard MA, Ohh M. (2004). Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 24: 1-13.
23. Ohh M. (2006). Ubiquitin pathway in VHL cancer syndrome. Neoplasia 8: 623-629.
24. Ohh M, Yauch RL, Lonergan K, Whaley JM, Stemmer-Rachamimov AO, Louis DN et al. (1998). The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1: 959-968.
25. Rizzo MA, Shome K, Vasudevan C, Stolz DB, Sung TC, Frohman MA et al. (1999). Phospholipase D and its product, phosphatidic acid, mediate agonist-dependent raf-1 translocation to the plasma membrane and the activation of the mitogen-activated protein kinase pathway. J Biol Chem 274: 1131-1139.
26. Rodrik V, Gomes E, Hui L, Rockwell P, Foster DA. (2006). Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. FEBS Lett 580: 5647-5652.
27. Rodrik V, Zheng Y, Harrow F, Chen Y, Foster DA. (2005). Survival signals generated by estrogen and phospholipase D in MCF-7breast cancer cells are dependent on Myc. Mol Cell Biol 25: 7917-7925.
28. Sawyers CL. (2003). Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4: 343-348.
29. Semenza GL. (2001). HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13: 167-171.
30. Shaw RJ. (2006). Glucose metabolism and cancer. Curr Opin Cell Biol 18: 598-608.
31. Shen Y, Xu L, Foster DA. (2001). Phospholipase D requirement for receptor-mediated endocytosis. Mol Cell Biol 21: 595-602.
32. Stickle NH, Chung J, Klco JM, Hill RP, Kaelin Jr WG, Ohh M. (2004). pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol 24: 3251-3261.
33. Sung TC, Altshuller YM, Morris AJ, Frohman MA. (1999). Molecular analysis of mammalian phospholipase D2. J Biol Chem 274: 494-502.
34. Sung TC, Roper RL, Zhang Y, Rudge SA, Temel R, Hammond SM et al. (1997). Mutagenesis of phospholipase D defines a superfamily including a trans-Golgi viral protein required for poxvirus pathogenicity. EMBO J 16: 4519-4530.
35. Zhao Y, Ehara H, Akao Y, Shamoto M, Nakagawa Y, Banno Y et al. (2000). Increased activity and intranuclear expression of phospholipase D2 in human renal cancer. Biochem Biophys Res Commun 278: 140-143.
36. Zheng Y, Rodrik V, Toschi A, Shi M, Hui L, Shen Y et al. (2006). Phospholipase D couples survival and migration signals in response to stress in human breast cancer cells. J Biol Chem 281: 15862-15868.
37. Zhong M, Shen Y, Zheng Y, Joseph T, Jackson D, Beychenok S et al. (2003). Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. Biochem Biophys Res Comm 302: 615-619.